For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

Rexulti (brexpiprazole) shares positive trial results for treating agitation in Alzheimer's. Following this a bumpy road for another Alzheimer's drug candidate that could supplant the need for antipsychotics to treat behavioral Alzheimer's symptoms, this could be the first such drug approved — if its safety and efficacy data stay on track.

Decision on Brexpiprazole for Alzheimer's Agitation Due in May

Drugs Archives - Alzheimer's & Dementia Weekly

Brexpiprazole (Rexulti): Uses, Side Effects, Warnings & More - GoodRx

FDA Approves First Drug to Treat Agitation Symptoms Associated

New approaches to symptomatic treatments for Alzheimer's disease

Controversy Surrounds Brexpiprazole's FDA Approval, a New

Schizophrenia drug promising for Alzheimer's agitation - Seasons

Rexulti backed for Alzheimer's agitation by FDA adcomm

JAMA Neurology Publishes Complete Results of Positive Phase 3

Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti

Frontiers Agitation and Dementia: Prevention and Treatment

Decision on Brexpiprazole for Alzheimer's Agitation Due in May

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

Targets, trials and tribulations in Alzheimer therapeutics